Structure Therapeutics Q3 loss widens on higher R&D costs
GPCR•Structure Therapeutics’ Q3 net loss was $144.76 million as operating expenses rose to $156.33 million. The company ended the quarter with $1.2 billion in cash and expects its cash runway to extend through 2028.
1. Quarterly results
Structure Therapeutics’ net loss widened year over year in the third quarter as operating expenses increased to $156.33 million. The company reported a net loss of $144.76 million; higher research and development expenses reflected increased clinical trial costs, preclinical research and employee expenses, while higher general and administrative costs were attributed to workforce and infrastructure expansion.
2. Cash and pipeline outlook
The company ended the quarter with $1.2 billion in cash and expects its cash runway to extend through 2028. It expects additional aleniglipron data from supplementary studies in the fourth quarter of 2026 and topline results from Phase 3 aleniglipron trials in the second half of 2028. Topline data from the ACCG-2671 multiple-ascending-dose clinical trial are expected in the first half of 2027.
